In This Section

A Comprehensive Cancer Center Designated by the National Cancer Institute

Select Publications

Developmental Research Program-Related Publications

Philip Connell, MD

  • Maacke H, Opitz S, Jost K, Hamdorf W, Henning W, Krüger S, Feller AC, Lopens A, Diedrich K, Schwinger E, Stürzbecher HW.  Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer. Int J Cancer 88:907-13, 2000.
  • Yoshikawa K, Ogawa T, Baer R, Hemmi H, Honda K, Yamauchi A, Inamoto T, Ko K, Yazumi S, Motoda H, Kodama H, Noguchi S, Gazdar AF, Yamaoka Y, Takahashi R.  Abnormal expression of BRCA1 and BRCA1-interactive DNA-repair proteins in breast carcinomas. Int J Cancer 88:28-36, 2000.
  • Henning W, Sturzbecher HW. Homologous recombination and cell cycle checkpoints: Rad51 in tumour progression and therapy resistance. Toxicology 193:91-109, 2003.
  • Russell JS, Brady K, Burgan WE, Cerra MA, Oswald KA, Camphausen K, Tofilon PJ.  Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity. Cancer Res 63:7377-83, 2003.
  • Connell PP, Siddiqui N, Hoffman S, Kuang A, Khatipov EA, Weichselbaum RR, Bishop DK.  A hot spot for RAD51C interactions revealed by a peptide that sensitizes cells to cisplatin. Cancer Res 64:3002-5, 2004.
  • Qiao GB, Wu YL, Yang XN, Zhong WZ, Xie D, Guan XY, Fischer D, Kolberg HC, Kruger S, Stuerzbecher HW.  High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients. Br J Cancer 93:137-43, 2005.
  • Ito M, Yamamoto S, Nimura K, Hiraoka K, Tamai K, Kaneda Y. Rad51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin. J Gene Med 7:1044-52, 2005.
  • Esashi F, Christ N, Gannon J, Liu Y, Hunt T, Jasin M, West SC. CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair. Nature 434:598-604, 2005.

Suzanne Conzen, MD

  • Pan D, Kocherginsky M, Conzen SD. Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptor-negative breast cancer. Cancer Res 71:6360-70, 2011.  PMC3514452
  • Luca F, Kashyap S, Southard C, Zou M, Witonsky D, Di Rienzo A, Conzen SD. Adaptive variation regulates the expression of the human SGK1 gene in response to stress. PLoS Genet 5:e1000489, 2009.  PMC2679193

Robert Doebele, MD, PhD

  • Menon J, Doebele RC, Gomes S, Bevilacqua E, Reindl KM, Rosner MR. A novel interplay between Rap1 and  PKA regulates induction of angiogenesis in prostate cancer. PLoS One. 2012;7(11):e49893. Epub 2012.
  • Pavon-Eternod M, Gomes S, Geslain R, Dai Q, Rosner MR, Pan T.  tRNA over-expression in breast cancer and functional consequences. Nucleic Acids Res 37:7268-80, 2009. PMC2790902
  • Cohen EE, Rosner MR. MicroRNA-regulated feed forward loop network.Cell Cycle 8:2477-8, 2009.
  • Dangi-Garimella S, Yun J, Eves EM, Newman M, Erkeland SJ, Hammond SM, Minn AJ, Rosner MR.  Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7.  EMBO J 28:347-58, 2009. PMC2646152
  • Cohen EE, Zhu H, Lingen MW, Martin LE, Kuo WL, Choi EA, Kocherginsky M, Parker JS, Chung CH, Rosner MR. A feed-forward loop involving protein kinase Calpha and microRNAs regulates tumor cell cycle. Cancer Res 69:65-74, 2009.  PMC2746005
  • Granovsky AE, Clark MC, McElheny D, Heil G, Hong J, Liu X, Kim Y, Joachimiak G, Joachimiak A, Koide S, Rosner MR. Raf kinase inhibitory protein function is regulated via a flexible pocket and novel phosphorylation-dependent mechanism. Mol Cell Biol 29:1306-20, 2009. PMC2643833
  • Kuo WL, Liu J, Mauceri H, Vokes EE, Weichselbaum R, Rosner MR, Cohen EE. Efficacy of the multi-kinase inhibitor enzastaurin is dependent on cellular signaling context.  Mol Cancer Ther 9:2814-24, 2010.  PMC2953602
  • Eves EM, Rosner MR.  MAP kinase regulation of the mitotic spindle checkpoint. Methods Mol Biol 661:497-505, 2010.
  • Yun J, Frankenberger CA, Kuo WL, Boelens MC, Eves EM, Cheng N, Liang H, Li WH, Ishwaran H, Minn AJ, Rosner MR. Signaling pathway for RKIP and Let-7 regulates and predicts metastatic breast cancer.  EMBO J 30:4500-14, 2011. PMC3230370
  • Menon J, Doebele RC, Gomes S, Bevilacqua E, Reindl KM, Rosner MR.  PKA regulates induction of angiogenesis in prostate cancer.  PLoS One 7:e49893, 2012.  PMC3499522
  • Minn AJ, Bevilacqua E, Yun J, Rosner MR.  Identification of novel metastasis suppressor signaling pathways for breast cancer.  Cell Cycle 11:2452-7, 2012.  PMC3404876
  • Frank SA, Rosner MR. Nonheritable cellular variability accelerates the evolutionary processes of cancer. PLoS Biol 10:e1001296, 2012.  PMC3317895
  • Bevilacqua E, Frankenberger CA, Rosner MR. RKIP suppresses breast cancer metastasis to the bone by regulating stroma-associated genes. Int J Breast Cancer 2012:124704, 2012.  PMC3296187
  • Martinho O, Granja S, Jaraquemada T, Caeiro C, Miranda-Gonçalves V, Honavar M, Costa P, Damasceno M, Rosner MR, Lopes JM, Reis RM.  Downregulation of RKIP is associated with poor outcome and malignant progression in gliomas.  PLoS One 7:e30769, 2012.  PMC3264629

M. Eileen Dolan, PhD

  • Cox NJ, Gamazon ER, Wheeler HE, Dolan ME. Clinical translation of cell-based pharmacogenomic discovery. Clin Pharmacol Ther 92:425-7, 2012.
  • Wheeler HE, Gamazon ER, Wing C, Njiaju UO, Njoku C, Baldwin RM, Owzar K, Jiang C, Watson D, Shterev I, Kubo M, Zembutsu H, Winer E, Hudis C, Shulman LN, Nakamura Y, Ratain MJ, Kroetz DL, Cox NJ, Dolan ME. Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of paclitaxel-induced sensory peripheral neuropathy. Clin Cancer Res 19:491-9, 2013. PMC3549006

Yang-Xin Fu, PhD

  • Park S, Jiang Z, Mortenson ED, Deng L, Radkevich-Brown O, Yang X, Sattar H, Wang Y, Brown NK, Greene M, Liu Y, Tang J, Wang S, Fu YX. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity.  Cancer Cell 18:160-70, 2010. PMC2923645

Kathleen Goss, PhD

  • Khramtsov AI, Khramtsova GF, Tretiakova M, Huo D, Olopade OI, Goss KH. Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol 176:2911-20, 2010.  PMC2877852
  • Prosperi JR, Goss KH.  A Wnt-ow of opportunity: Targeting the Wnt/b-catenin pathway in breast cancer.  Current Drug Targets 11:1074-88, 2010.
  • Miller ME, Kunnavakkam R, Khramtsova G, Khramtsov A, Sylvester BE, Huo D, Olopade OI, Goss KH. Analysis of Wnt signaling as a determinant of racial disparity in colorectal cancer outcomes. Cancer Epidemiology Biomarkers and Prevention, submitted, 2013.
  • Xu J, Prosperi JR, Olopade OI, Goss KH.  b-catenin is required for the tumorigenic behavior of triple-negative breast cancer cells.  Oncogene, submitted, 2013.

Dezheng Huo, MD, PhD

  • Zheng Y, Huo D, Zhang J, Yoshimatsu TF, Niu Q, Olopade OI.  Microsatellites in the estrogen receptor (ESR1, ESR2) and androgen receptor (AR) genes and breast cancer risk in African American and Nigerian women. PLoS One 7:e40494, 2012.  PMC3394707
  • Zheng Y, Ogundiran TO, Falusi AG, Nathanson KL, John EM, Hennis AJ, Ambs S, Domchek SM, Rebbeck TR, Simon MS, Nemesure B, Wu SY, Leske MC, Odetunde A, Niu Q, Zhang J, Afolabi C, Gamazon ER, Cox NJ, Olopade CO, Olopade OI, Huo D. Fine-mapping of breast cancer genome-wide association studies loci in women of African ancestry identifies novel susceptibility markers. Carcinogenesis, Epub ahead of print, 2013.

Richard B. Jones, PhD

  • Ciaccio MF, Wagner JP, Chuu CP, Lauffenburger DA, Jones RB. Systems analysis of EGF receptor signaling dynamics with microwestern arrays. Nat Methods 7:148-55, 2010.  PMC2881471

Anthony Kossiakoff, PhD

  • Rizk SS, Luchniak A, UysalS, Brawley CM, Rock RS, Kossiakoff AA.  An engineered substance P variant for receptor-mediated delivery of synthetic antibodies into tumor cells.  Proc Natl Acad Sci USA 106:11011-5, 2009.  PMC2708752
  • Rizk SS, Misiura A, Paduch M, Kossiakoff AA. Substance P derivate is as versatile tools for specific delivery of varius types of biomolecular cargo. Bioconjug Chem 18:42-3, 2012.  PMC3268364

Marvin Makinen, PhD

  • Makinen MW, Shen S, Conzen SD, Machado II, AJ, Yun D, Xie QG, Kao CM, Chen CT.  Can Vanadyl Chelates Help To Detect Cancer?  Sixth Intern Symp Chem & Biol Vanadium, Gulbenkian Foundation, Lisbon, Portugal, July, 2008 (abstract).
  • Mustafi D, Peng B, Foxley S, Makinen MW, Karczmar GS, Zamora M, Ejnik J, Martin H.  New vanadium-based magnetic resonance imaging probes: Clinical potential for early detection of cancer.  J Biol Inorg Chem 14:1187-97, 2009.
  • Makinen MW, Shen S, Conzen SD, Machado II, AJ, Yun D, Xie QG, Kao CM, Chen CT.  Can Vanadyl (VO2+) Chelates Enhance Cancer Detection by FDG PET Imaging? Wuhan Optoelectronics Forum Series, Wuhan, China, 1:75-90, 2009.
  • Makinen MW, Bamba R, Ikejimba L, Wietholt C, Chen CT, Conzen SD. The vanadyl chelate bis(acetylacetonato)oxovanadium(IV) increases the fractional uptake of2-(fluorine-18)-2-deoxy-D-glucose by cultured human breast carcinoma cells.  Dalton Trans, Epub ahead of print, 2013.